Bio Accounts Payable vs Other Current Liab Analysis

BIO Stock

USD 294.08 1.65 0.56%

Bio Rad financial indicator trend analysis is way more than just evaluating Bio Rad Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Rad Laboratories is a good investment. Please check the relationship between Bio Rad Accounts Payable and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

Accounts Payable vs Other Current Liab

Accounts Payable vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Rad Laboratories Accounts Payable account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Bio Rad's Accounts Payable and Other Current Liab is 0.3. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Bio Rad Laboratories, assuming nothing else is changed. The correlation between historical values of Bio Rad's Accounts Payable and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Bio Rad Laboratories are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Accounts Payable i.e., Bio Rad's Accounts Payable and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Bio Rad obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bio Rad Laboratories are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Liab

Most indicators from Bio Rad's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

At this time, Bio Rad's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 1 B, while Selling General Administrative is likely to drop about 481.6 M.

	2021	2022	2023	2024 (projected)
Gross Profit	1.6B	1.6B	1.4B	769.3M
Total Revenue	2.9B	2.8B	2.7B	1.4B

Gross Profit Total Revenue

Bio Rad fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Accounts Payable	Intangible Assets	Common Stock Total Equity	Common Stock
Total Assets		0.27	-0.41	0.51	1.0	0.85	0.14	1.0	0.3	0.99	-0.97	0.71	0.4	0.46	0.97	0.71	-0.02	-0.19	0.98	0.93	0.69	0.08	0.58	0.42	-0.37	-0.37
Short Long Term Debt Total	0.27		-0.75	-0.03	0.22	0.43	0.95	0.27	-0.08	0.18	-0.05	0.81	0.28	0.22	0.47	0.63	0.23	-0.7	0.45	0.52	0.76	0.0	-0.28	0.51	-0.33	-0.33
Other Current Liab	-0.41	-0.75		0.13	-0.38	-0.45	-0.75	-0.44	0.24	-0.36	0.27	-0.61	-0.02	-0.04	-0.54	-0.56	0.08	0.86	-0.5	-0.67	-0.58	-0.01	0.3	-0.22	0.1	0.1
Total Current Liabilities	0.51	-0.03	0.13		0.5	0.72	-0.29	0.46	0.85	0.48	-0.49	0.43	0.72	0.78	0.4	0.53	0.37	0.48	0.5	0.34	0.5	0.59	0.69	0.39	-0.7	-0.7
Total Stockholder Equity	1.0	0.22	-0.38	0.5		0.83	0.08	1.0	0.3	1.0	-0.98	0.67	0.38	0.44	0.96	0.68	-0.04	-0.16	0.97	0.92	0.65	0.08	0.59	0.39	-0.35	-0.35
Property Plant And Equipment Net	0.85	0.43	-0.45	0.72	0.83		0.2	0.82	0.55	0.8	-0.74	0.84	0.65	0.78	0.83	0.92	0.26	-0.06	0.88	0.85	0.89	0.29	0.6	0.48	-0.72	-0.72
Net Debt	0.14	0.95	-0.75	-0.29	0.08	0.2		0.15	-0.38	0.06	0.06	0.64	0.07	-0.04	0.35	0.44	0.12	-0.81	0.3	0.41	0.57	-0.13	-0.45	0.38	-0.07	-0.07
Retained Earnings	1.0	0.27	-0.44	0.46	1.0	0.82	0.15		0.25	0.99	-0.97	0.69	0.34	0.4	0.97	0.67	-0.06	-0.23	0.97	0.93	0.67	0.09	0.53	0.39	-0.31	-0.31
Cash	0.3	-0.08	0.24	0.85	0.3	0.55	-0.38	0.25		0.27	-0.28	0.32	0.7	0.76	0.21	0.42	0.37	0.54	0.31	0.18	0.39	0.37	0.6	0.37	-0.73	-0.73
Non Current Assets Total	0.99	0.18	-0.36	0.48	1.0	0.8	0.06	0.99	0.27		-0.99	0.63	0.34	0.39	0.95	0.63	-0.08	-0.16	0.95	0.9	0.61	0.07	0.58	0.36	-0.3	-0.3
Non Currrent Assets Other	-0.97	-0.05	0.27	-0.49	-0.98	-0.74	0.06	-0.97	-0.28	-0.99		-0.53	-0.3	-0.36	-0.9	-0.54	0.12	0.08	-0.91	-0.85	-0.51	-0.08	-0.62	-0.31	0.24	0.24
Cash And Short Term Investments	0.71	0.81	-0.61	0.43	0.67	0.84	0.64	0.69	0.32	0.63	-0.53		0.55	0.57	0.81	0.89	0.22	-0.39	0.82	0.83	0.97	0.16	0.28	0.59	-0.58	-0.58
Net Receivables	0.4	0.28	-0.02	0.72	0.38	0.65	0.07	0.34	0.7	0.34	-0.3	0.55		0.88	0.4	0.71	0.74	0.3	0.46	0.37	0.68	0.02	0.56	0.76	-0.88	-0.88
Common Stock Shares Outstanding	0.46	0.22	-0.04	0.78	0.44	0.78	-0.04	0.4	0.76	0.39	-0.36	0.57	0.88		0.42	0.8	0.64	0.39	0.5	0.41	0.72	0.13	0.67	0.54	-0.97	-0.97
Non Current Liabilities Total	0.97	0.47	-0.54	0.4	0.96	0.83	0.35	0.97	0.21	0.95	-0.9	0.81	0.4	0.42		0.76	0.01	-0.35	0.99	0.97	0.78	0.0	0.44	0.51	-0.37	-0.37
Inventory	0.71	0.63	-0.56	0.53	0.68	0.92	0.44	0.67	0.42	0.63	-0.54	0.89	0.71	0.8	0.76		0.43	-0.18	0.79	0.8	0.97	0.07	0.45	0.57	-0.78	-0.78
Other Current Assets	-0.02	0.23	0.08	0.37	-0.04	0.26	0.12	-0.06	0.37	-0.08	0.12	0.22	0.74	0.64	0.01	0.43		0.26	0.06	-0.02	0.39	-0.12	0.11	0.59	-0.7	-0.7
Other Stockholder Equity	-0.19	-0.7	0.86	0.48	-0.16	-0.06	-0.81	-0.23	0.54	-0.16	0.08	-0.39	0.3	0.39	-0.35	-0.18	0.26		-0.28	-0.45	-0.28	0.15	0.62	-0.14	-0.29	-0.29
Total Liab	0.98	0.45	-0.5	0.5	0.97	0.88	0.3	0.97	0.31	0.95	-0.91	0.82	0.46	0.5	0.99	0.79	0.06	-0.28		0.96	0.81	0.09	0.5	0.52	-0.45	-0.45
Property Plant And Equipment Gross	0.93	0.52	-0.67	0.34	0.92	0.85	0.41	0.93	0.18	0.9	-0.85	0.83	0.37	0.41	0.97	0.8	-0.02	-0.45	0.96		0.81	0.01	0.36	0.47	-0.37	-0.37
Total Current Assets	0.69	0.76	-0.58	0.5	0.65	0.89	0.57	0.67	0.39	0.61	-0.51	0.97	0.68	0.72	0.78	0.97	0.39	-0.28	0.81	0.81		0.1	0.35	0.64	-0.73	-0.73
Short Term Debt	0.08	0.0	-0.01	0.59	0.08	0.29	-0.13	0.09	0.37	0.07	-0.08	0.16	0.02	0.13	0.0	0.07	-0.12	0.15	0.09	0.01	0.1		0.11	-0.22	-0.07	-0.07
Accounts Payable	0.58	-0.28	0.3	0.69	0.59	0.6	-0.45	0.53	0.6	0.58	-0.62	0.28	0.56	0.67	0.44	0.45	0.11	0.62	0.5	0.36	0.35	0.11		0.15	-0.51	-0.51
Intangible Assets	0.42	0.51	-0.22	0.39	0.39	0.48	0.38	0.39	0.37	0.36	-0.31	0.59	0.76	0.54	0.51	0.57	0.59	-0.14	0.52	0.47	0.64	-0.22	0.15		-0.64	-0.64
Common Stock Total Equity	-0.37	-0.33	0.1	-0.7	-0.35	-0.72	-0.07	-0.31	-0.73	-0.3	0.24	-0.58	-0.88	-0.97	-0.37	-0.78	-0.7	-0.29	-0.45	-0.37	-0.73	-0.07	-0.51	-0.64		1.0
Common Stock	-0.37	-0.33	0.1	-0.7	-0.35	-0.72	-0.07	-0.31	-0.73	-0.3	0.24	-0.58	-0.88	-0.97	-0.37	-0.78	-0.7	-0.29	-0.45	-0.37	-0.73	-0.07	-0.51	-0.64	1.0

Click cells to compare fundamentals

Bio Rad Account Relationship Matchups

Bio Rad fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.0B	13.0B	17.8B	13.5B	12.3B	12.9B
Short Long Term Debt Total	439.8M	14.1M	11.0M	1.2B	1.4B	1.5B
Other Current Liab	158.5M	224.9M	210.7M	186.2M	(35.4B)	(33.6B)
Total Current Liabilities	905.5M	631.5M	680.9M	568.7M	522.8M	338.4M
Total Stockholder Equity	5.8B	9.9B	13.7B	9.6B	8.7B	9.2B
Property Plant And Equipment Net	701.2M	693.5M	695.8M	679.6M	723.7M	759.9M
Net Debt	(220.9M)	(648.1M)	(459.8M)	764.0M	1.0B	1.1B
Retained Earnings	5.5B	9.3B	13.5B	9.9B	9.3B	9.7B
Cash	660.7M	662.2M	470.8M	434.2M	404.0M	257.1M
Non Current Assets Total	5.8B	10.8B	15.8B	10.3B	9.3B	9.7B
Non Currrent Assets Other	(997.7B)	(2.1T)	(3.1T)	(1.8T)	(1.5T)	(1.4T)
Cash And Short Term Investments	1.1B	996.7M	875.5M	1.8B	1.6B	1.7B
Net Receivables	392.7M	419.4M	423.5M	494.6M	500.9M	272.8M
Common Stock Shares Outstanding	30.2M	30.2M	30.2M	29.8M	29.2M	29.1M
Liabilities And Stockholders Equity	8.0B	13.0B	17.8B	13.5B	12.3B	12.9B
Non Current Liabilities Total	1.3B	2.5B	3.4B	3.3B	3.0B	3.2B
Inventory	554.0M	622.3M	572.2M	719.3M	780.5M	819.5M
Other Current Assets	113.3M	101.5M	117.8M	147.8M	154.0M	91.6M
Other Stockholder Equity	371.6M	329.5M	335.4M	183.9M	(183.5M)	(174.3M)
Total Liab	2.3B	3.1B	4.1B	3.9B	3.6B	3.7B
Property Plant And Equipment Gross	701.2M	1.5B	1.5B	1.5B	1.8B	1.9B
Total Current Assets	2.2B	2.1B	2.0B	3.2B	3.0B	3.2B
Accumulated Other Comprehensive Income	(87.3M)	282.5M	(175.6M)	(466.8M)	(336.0M)	(319.2M)
Short Term Debt	426.2M	1.8M	489K	465K	41.4M	30.8M
Accounts Payable	287.1M	362.3M	418.9M	329.8M	142.8M	138.4M
Intangible Assets	145.5M	199.5M	253.9M	332.1M	320.5M	188.7M
Other Assets	40.3M	13K	82K	94.6M	85.1M	71.4M
Long Term Debt	13.6M	12.3M	10.5M	1.2B	1.2B	1.3B
Good Will	264.1M	291.9M	347.3M	406.5M	413.6M	339.1M
Treasury Stock	(38.4M)	(99.9M)	(106.3M)	(263.6M)	(237.2M)	(225.4M)
Property Plant Equipment	499.3M	491.4M	695.8M	498.6M	573.4M	371.9M
Current Deferred Revenue	33.7M	42.5M	50.9M	52.2M	35.8B	37.5B
Other Liab	1.2B	2.4B	3.4B	2.0B	2.3B	2.4B
Short Term Investments	459.5M	334.5M	404.7M	1.4B	1.2B	1.3B
Net Tangible Assets	5.8B	9.9B	13.1B	9.2B	10.6B	11.1B
Retained Earnings Total Equity	5.5B	9.3B	13.5B	9.9B	11.4B	12.0B
Capital Surpluse	410.0M	429.4M	441.7M	447.5M	514.6M	366.5M
Deferred Long Term Liab	997.8M	2.1B	3.1B	1.8B	2.0B	2.1B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Rad's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Bio Stock analysis

When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Global Correlations Find global opportunities by holding instruments from different markets
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

4.797

Earnings Share

(10.68)

Revenue Per Share

90.024

Quarterly Revenue Growth

(0.1)

Return On Assets

0.0169

The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Accounts Payable vs Other Current Liab Analysis

Accounts Payable vs Other Current Liab

Accounts Payable vs Other Current Liab Correlation Analysis

Correlation Coefficient

Accounts Payable

Other Current Liab

Bio Rad fundamental ratios Correlations

Bio Rad Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bio Rad fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Bio Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets

Non Currrent Assets Other	- 0.99	Non Current Assets Total
Non Currrent Assets Other	- 0.98	Total Stockholder Equity
Common Stock	- 0.97	Common Stock Shares Outstanding
Common Stock Total Equity	- 0.97	Common Stock Shares Outstanding
Non Currrent Assets Other	- 0.97	Retained Earnings
Non Currrent Assets Other	- 0.97	Total Assets